Our group has demonstrated that intravenous administration of apotransferrin strongly reduces the brain damage (up to 75%) in 3 different rat models including both transient and permanent ischemic stroke and improves the neurological impairment (neuroscore 60%) induced by stroke. Thus, this new approach may benefit not only stroke patients who can be treated with current treatment to induce recanalization (transient stroke) but also the 80% of patients who could not benefit from current therapies directed to induce recanalization of the artery (permanent strokes).
Results in the preclinical area and some results obtained in serum of stroke patients lead us to think that apotransferrin is a good neuroprotector in the early stages of the ischemic event.
Description of the technology
The invention relates to the use of intravenous apotransferrin to prevent damage induced by permanent and also transient ischemic stroke. Moreover, we hold and International Patent Application (PCT) protecting the use of apotransferrin in brain stroke. Each year, 15 million new stroke cases occur worldwide (source: WHO). Despite the present knowledge of the pathophysiology of brain ischemic events, stroke remains as one of the leading causes of death and disability due to the lack of effective therapies. Current stroke treatments are based on thrombus removal and these can be only prescribed in less than 20 % of stroke patients. Therefore, stroke therapy remains a dire need, and the development of successful therapeutic strategies represent an opportunity.
Specifications
The mechanism involved in protection by apotransferrin is diferent from those previously targeted in stroke and it is not dependent on the blockade of the NMDA receptor or on direct free radical scavenging. Our group found that apotransferrin prevents the import by neurons of the prooxidant iron-loaded-transferrin in excitotoxic conditions. By doing so, apotransferrin prevents the burst of free radical production inside the neuron rather than acting as a classic antioxidant molecule that scavenges or removes free radicals once produced.
Main advantages of its use
Applications
Additional information (attached documents)
MISSIONS
The mission of the Health Sciences Research Institute of the “Germans Trias i Pujol” Foundation (IGTP) are to generate, preserve, disseminate and increase multidisciplinary and translational knowledge, as well as echnological development in biomedical sciences, by means of a dynamic, efficient and effective organisation.
GOALS
The ultimate goal of the IGTP is to become a research centre of reference, able to transfer the generated knowledge into clinical practice and therapeutics (translationality), in order to optimise the psychophysical health and quality of life of the population.
VISION
- The IGTP, as an institution devoted to biomedical research:
- Assumes its humanitarian view, ethical principles, and solidarity, as well as the principles of sustainability in resource management and relationship with the environment.
- Its activities will be always related with the health needs of the population and the priority areas in healthcare development.
- Assumes the scientific method as its own and faces its goals by means of programs of excellence which enable the leadership in the areas of knowledge of the interest of its researchers.
- Protects the data used in, and generated by the research programmes, as well as the privacy of the patients and healthy individuals who participate in them.
Create your free account to connect with Germans Trias i Pujol Health Sciences Research Institute and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Germans Trias i Pujol Health Sciences Research Institute
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
